ClinicalTrials.gg

Program

zanidatamab

Also written as “Zanidatamab” and “ZW25 (Zanidatamab)”.

Its studies are mostly in Breast Neoplasms · Biliary Tract Neoplasms · Stomach Neoplasms, led by 2 companies.

Furthest: phase 3, since Nov 5, 202111 company-led studies, 5 open or runningNext primary completion: Dec 31, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jazz Pharmaceuticals105 open or runningphase 3since Nov 5, 2021Aug 23, 2016Dec 31, 2026phase 2 · NCT06695845
BeOne Medicines10 open or runningphase 3since Nov 14, 2019Nov 14, 2019none ahead

Also a collaborator on its studies: jazz-pharmaceuticals-ireland-limited and alx-oncology-inc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 23, 2016First study: phase 1 study in Breast NeoplasmsNew to Jazz PharmaceuticalsJazz Pharmaceuticals · NCT02892123 · 279 enrolled · United States, Canada, Korea, Republic of
  2. Feb 22, 2019Phase 2 study in Biliary Tract NeoplasmsJazz Pharmaceuticals · NCT03929666 · 74 enrolled · United States, Canada, Chile and more
  3. Nov 14, 2019BeOne Medicines's first study: phase 3 study in Advanced MalignanciesNew to BeOne MedicinesBeOne Medicines · NCT04164199 · 404 enrolled · United States, Australia, China and more
  4. Jan 7, 2020Phase 2 study in Breast NeoplasmsJazz Pharmaceuticals · NCT04224272 · 51 enrolled · United States, Canada, Spain
  5. Jul 6, 2020Phase 2 study in Biliary Tract NeoplasmsJazz Pharmaceuticals · NCT04466891 · 87 enrolled · United States, Canada, Chile and more
  6. Aug 23, 2021Phase 2 study in HER2-expressing CancersJazz Pharmaceuticals · NCT05027139 · 52 enrolled · United States
  7. Nov 5, 2021Phase 3 study in Stomach NeoplasmsJazz Pharmaceuticals · NCT05152147 · 920 enrolled · Argentina, Australia, Belgium and more
  8. Feb 21, 2024Phase 3 study in Biliary Tract NeoplasmsJazz Pharmaceuticals · NCT06282575 · 286 planned · United States, Argentina, Belgium and more
  9. May 24, 2024Phase 3 study in Metastatic HER2-positive Breast CancerJazz Pharmaceuticals · NCT06435429 · 550 planned · United States, Australia, Austria and more
  10. Nov 16, 2024Phase 2 study in Breast NeoplasmsJazz Pharmaceuticals · NCT06695845 · 200 planned · United States, Georgia, South Korea and more
  11. Jul 28, 2025Phase 2 study in Breast NeoplasmsJazz Pharmaceuticals · NCT07102381 · 125 planned · United States, Germany, Italy and more

Ahead

  1. Dec 31, 2026Primary completion: phase 2 study in Breast NeoplasmsJazz Pharmaceuticals · NCT06695845
  2. Dec 29, 2027Primary completion: phase 2 study in Breast NeoplasmsJazz Pharmaceuticals · NCT07102381
  3. Apr 28, 2028Primary completion: phase 3 study in Metastatic HER2-positive Breast CancerJazz Pharmaceuticals · NCT06435429
  4. Dec 1, 2028Primary completion: phase 3 study in Biliary Tract NeoplasmsJazz Pharmaceuticals · NCT06282575

TargetBeta

ERBB2 →read by rule
“An engineered immunoglobulin G1 (IgG1) bi-specific monoclonal antibody that targets two different non-overlapping epitopes of the human tumor-associated antigen (TAA) epidermal growth factor receptor 2 (HER2), ECD2 and ECD4, ”NCIt, by rule
“Receptor protein-tyrosine kinase erbB-2 inhibitor”ChEMBL 37, by rule

Other programs on ERBB2

ProgramCompanyFurthest phaseStudies
TrastuzumabruleHoffmann-La Rochephase 485
pertuzumabruleHoffmann-La Rochephase 456
trastuzumab deruxtecanruleDaiichi Sankyophase 449
tucatinibrulePfizerphase 425
disitamab vedotinRemeGenphase 336
trastuzumab rezetecanruleJiangsu HengRui Medicinephase 336
Lutetium-177Novartisphase 324
trastuzumab brengitecanSichuan Biokin Pharmaceuticalphase 321
Gallium-68Philogenphase 317
zongertinibruleBoehringer Ingelheimphase 315
Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102Sino Biopharmaceuticalphase 313
sunvozertinibruleDizal Pharmaceuticalsphase 312

Studies

All 11 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07102381Breast Neoplasms · United States, Germany, Italy and more2RecruitingJazz PharmaceuticalsDec 29, 2027125
NCT06695845Breast Neoplasms · United States, Georgia, South Korea and more2RecruitingJazz PharmaceuticalsDec 31, 2026200
NCT06435429Metastatic HER2-positive Breast Cancer · United States, Australia, Austria and more3RecruitingJazz PharmaceuticalsApr 28, 2028550
NCT06282575Biliary Tract Neoplasms · United States, Argentina, Belgium and more3RecruitingJazz PharmaceuticalsDec 1, 2028286
NCT05152147Stomach Neoplasms · Argentina, Australia, Belgium and more3Active, not recruitingJazz PharmaceuticalsJul 15, 2026920
NCT05027139HER2-expressing Cancers · United States2CompletedJazz PharmaceuticalsAug 29, 202552
NCT04466891Biliary Tract Neoplasms · United States, Canada, Chile and more2CompletedJazz PharmaceuticalsJul 28, 202387
NCT04224272Breast Neoplasms · United States, Canada, Spain2CompletedJazz PharmaceuticalsApr 28, 202351
NCT04164199Advanced Malignancies · United States, Australia, China and more3CompletedBeOne MedicinesMay 23, 2026404
NCT03929666Biliary Tract Neoplasms · United States, Canada, Chile and more2CompletedJazz PharmaceuticalsAug 30, 202574
NCT02892123Breast Neoplasms · United States, Canada, Korea, Republic of1CompletedJazz PharmaceuticalsOct 31, 2024279

How it is read

Names in the registry

  • “Zanidatamab”, 7 entries
  • “ZW25 (Zanidatamab)”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.